Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 90
Inquire Before Buying

Global Markets Direct's, ‘Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)

  • The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects

  • The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Interstitial Cystitis (Painful Bladder Syndrome) Overview 8
Therapeutics Development 9
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview 9
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis 10
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies 11
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes 12
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies 16
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes 17
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development 18
Allergan Plc 19
Aquinox Pharmaceuticals Inc. 20
Astellas Pharma Inc. 21
Kytogenics Pharmaceuticals, Inc. 22
Lipella Pharmaceuticals, Inc. 23
MediPost Co., Ltd. 24
UCB S.A. 25
Urigen Pharmaceuticals, Inc. 26
UroGen Pharmaceuticals, Ltd. 27
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(heparin + lidocaine) - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AQX-1125 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ASP-6294 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Cartistem - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
certolizumab pegol - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
GM-0111 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
lidocaine hydrochloride - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
LP-08 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
mesalamine - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
MK-7264 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
NEO-5937 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
onabotulinumtoxinA - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
onabotulinumtoxinA SR - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
pentosan polysulfate sodium - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
URG-801 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects 77
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products 78
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones 79
Featured News & Press Releases 79
May 25, 2016: Aquinox Announces Executive Appointments 79
May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results 79
May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego 81
Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA 81
Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration 82
Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference 82
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis 83
Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS 84
Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 84
Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 84
Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis 85
May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms 85
Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 86
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 87
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2016 9
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 18
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan Plc, H2 2016 19
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016 20
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc., H2 2016 21
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H2 2016 22
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H2 2016 23
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by MediPost Co., Ltd., H2 2016 24
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB S.A., H2 2016 25
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H2 2016 26
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016 27
Assessment by Monotherapy Products, H2 2016 28
Assessment by Combination Products, H2 2016 29
Number of Products by Stage and Target, H2 2016 31
Number of Products by Stage and Mechanism of Action, H2 2016 33
Number of Products by Stage and Route of Administration, H2 2016 35
Number of Products by Stage and Molecule Type, H2 2016 37
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H2 2016 77
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H2 2016 78

List of Figures

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2016 9
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Targets, H2 2016 30
Number of Products by Stage and Targets, H2 2016 30
Number of Products by Mechanism of Actions, H2 2016 32
Number of Products by Stage and Mechanism of Actions, H2 2016 32
Number of Products by Routes of Administration, H2 2016 34
Number of Products by Stage and Routes of Administration, H2 2016 34
Number of Products by Molecule Types, H2 2016 36
Number of Products by Stage and Molecule Types, H2 2016 36
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2017
    Published: 19-Sep-2017        Price: US 2000 Onwards        Pages: 90
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2017, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline landscape.Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to ......
  • Global Overactive Bladder Therapeutics Market Research Report 2017
    Published: 14-Sep-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Overactive Bladder Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Overactive Bladder Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America - Eu......
  • Pyelonephritis - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 69
    Pyelonephritis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H2 2017, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape. Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, freque......
  • Global Urinary Tract Infection Treatment Market 2017-2021
    Published: 09-Aug-2017        Price: US 3500 Onwards        Pages: 78
    About Urinary Tract Infection Treatment UTI is an infection occurred in any part of the urinary system. The infection mostly involves the lower part of the urinary tract. UTI can be classified into different types depending on the portion of the urinary system affected. Women are comparatively at a higher risk of developing UTI as compared with men since the urethra of the women is comparatively smaller than men and is also closer to the anus. This anatomical structure of the urinary trac......
  • Global Overactive Bladder Industry Market Research 2017
    Published: 02-Aug-2017        Price: US 2600 Onwards        Pages: 163
    In this report, we analyze the Overactive Bladder industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2012 to 2017. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2012 to 2017. We also make a......
  • Premature Ejaculation - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Premature Ejaculation-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Premature Ejaculation. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Premature Ejaculation by development stage, therapy type, route of administration and molecule type is also covered in the rep......
  • Pyelonephritis - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Pyelonephritis-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Pyelonephritis. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Pyelonephritis by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a sp......
  • Premature Ejaculation - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Premature Ejaculation -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Premature Ejaculation in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Premature Ejaculation. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Premature Ejaculation. The report contains the targeted......
  • Premature Ejaculation - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 28-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Premature Ejaculation - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Premature Ejaculation for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Premature Ejaculation . It enables underst......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs